Interleukin-8 in inflammatory rheumatic diseases : synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thiomalate and methotrexate

• Published in: Rheumatology international 1992-09, Vol.12 (4), p.159-164
• Main Authors: SEITZ, M, DEWALD, B, CESKA, M, GERBER, N, BAGGIOLINI, M
• Format: Article
• Language: English
• Subjects: Anti-Inflammatory Agents - pharmacology; Arthritis, Psoriatic - metabolism; Arthritis, Rheumatoid - metabolism; Biological and medical sciences; Bones, joints and connective tissue. Antiinflammatory agents; Gold Sodium Thiomalate - pharmacology; Humans; Immunoglobulin M - metabolism; Interleukin-8 - metabolism; Medical sciences; Methotrexate - pharmacology; Monocytes - metabolism; Pharmacology. Drug treatments; Rheumatic Diseases - metabolism; Rheumatoid Factor - metabolism; Synovial Fluid - metabolism
• ISSN: 0172-8172; 1437-160X
• DOI: 10.1007/bf00274936

The content of interleukin-8 (IL-8) in the synovial fluid and its production by blood and synovial fluid mononuclear cells (PBMC and SFMC) was compared in rheumatoid arthritis (RA) and various other inflammatory rheumatic disorders. The study included 125 patients and 20 healthy individuals. The highest concentrations of IL-8 were found in the synovial fluids and culture supernatants of PBMC and SFMC from patients with seropositive RA. Only PBMC from seropositive patients, and not from other rheumatic diseases, exhibited significant spontaneous release of IL-8 that correlated with serum IgM rheumatoid factor titers. Gold sodium thiomalate (GST) and methotrexate (MTX) inhibited the spontaneous and stimulated IL-8 production by PBMC by 55-86% at 50 and 10 micrograms/ml, respectively. Two main conclusions were drawn: (1) rheumatoid factors appeared to be a major cause of enhanced IL-8 production in seropositive RA, and (2) inhibition of IL-8-mediated neutrophil migration and activation could be part of the mechanism of action of GST and MTX.